Literature DB >> 8324862

Two-dose measles vaccination schedules.

S R Rosenthal1, C J Clements.   

Abstract

As measles continues to exact a high toll on infant mortality, particularly in developing countries, optimal strategies for the control of the disease are under discussion. As part of this debate, the place of 2-dose measles immunization schedules is reviewed regarding their potential as a strategy to improve measles control. To date, WHO has not recommended the use of a 2-dose schedule. A number of industrialized countries have already adopted a 2-dose schedule, often choosing to administer measles vaccine in the same injection as mumps and rubella vaccines. However, at present not enough is known about such schedules in developing countries to make global recommendations. Further research should include randomized controlled trials of early 2-dose schedules to investigate both technical and epidemiological issues such as the effect of blunting immunity and the duration of antibody. Long-term safety should be determined through studies of adequate size. Programmes already using 2-dose schedules are encouraged to evaluate their impact on disease incidence, cost, vaccine usage, and effect on coverage. Until further evaluation is complete, a high and timely coverage with one dose of measles vaccine in all areas remains the first priority for all immunization programmes.

Entities:  

Keywords:  Age Factors; Case Control Studies; Child; Clinical Research; Clinical Trials; Delivery Of Health Care; Demographic Factors; Developed Countries; Developing Countries; Diseases; Health; Health Services; Immunization; Infant; International Agencies; Logistics; Management; Mathematical Model; Measles--prevention and control; Models, Theoretical; Organization And Administration; Organizations; Population; Population Characteristics; Primary Health Care; Research Activities; Research Methodology; Studies; Un; Vaccination; Viral Diseases; Who; Youth

Mesh:

Substances:

Year:  1993        PMID: 8324862      PMCID: PMC2393510     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  Measles outbreaks in the Mozambican refugee camps in Malawi: the continued need for an effective vaccine.

Authors:  J D Porter; M Gastellu-Etchegorry; I Navarre; G Lungu; A Moren
Journal:  Int J Epidemiol       Date:  1990-12       Impact factor: 7.196

Review 2.  Measles vaccines.

Authors:  L E Markowitz; W A Orenstein
Journal:  Pediatr Clin North Am       Date:  1990-06       Impact factor: 3.278

3.  Measles among under-9-month-olds in rural Bangladesh: its significance for age at immunization.

Authors:  V Fauveau; J Chakraborty; A M Sarder; M A Khan; M A Koenig
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

4.  Epidemic measles in a highly vaccinated population.

Authors:  D M Shasby; T C Shope; H Downs; K L Herrmann; J Polkowski
Journal:  N Engl J Med       Date:  1977-03-17       Impact factor: 91.245

5.  The force of measles infection in East Africa.

Authors:  J Remme; M P Mandara; J Leeuwenburg
Journal:  Int J Epidemiol       Date:  1984-09       Impact factor: 7.196

6.  A review of data on measles cases from sentinel surveillance sites in north-western Nigeria.

Authors:  J O Chikwem; J Erb
Journal:  Public Health       Date:  1992-01       Impact factor: 2.427

7.  Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active/passive immunization.

Authors:  J Wilkins; P F Wehrle
Journal:  J Pediatr       Date:  1979-06       Impact factor: 4.406

8.  Effect of early immunization on antibody response to reimmunization with measles vaccine as demonstrated by enzyme-linked immunosorbent assay (ELISA).

Authors:  M D Murphy; P A Brunell; A W Lievens; Z M Shehab
Journal:  Pediatrics       Date:  1984-07       Impact factor: 7.124

9.  Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines.

Authors:  L E Markowitz; J Sepulveda; J L Diaz-Ortega; J L Valdespino; P Albrecht; E R Zell; J Stewart; M L Zarate; R H Bernier
Journal:  N Engl J Med       Date:  1990-03-01       Impact factor: 91.245

10.  Impact of revaccinating children who initially received measles vaccine before 10 months of age.

Authors:  H C Stetler; W A Orenstein; R H Bernier; K L Herrmann; B Sirotkin; D Hopfensperger; R Schuh; P Albrecht; A W Lievens; P A Brunell
Journal:  Pediatrics       Date:  1986-04       Impact factor: 7.124

  10 in total
  12 in total

1.  Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine.

Authors:  M Paunio; H Peltola; M Valle; I Davidkin; M Virtanen; O P Heinonen
Journal:  J Epidemiol Community Health       Date:  1999-03       Impact factor: 3.710

2.  Modelling the first dose of measles vaccination: the role of maternal immunity, demographic factors, and delivery systems.

Authors:  C J E Metcalf; P Klepac; M Ferrari; R F Grais; A Djibo; B T Grenfell
Journal:  Epidemiol Infect       Date:  2010-06-07       Impact factor: 2.451

Review 3.  Measles, the need for a paradigm shift.

Authors:  Emilie Javelle; Philippe Colson; Philippe Parola; Didier Raoult
Journal:  Eur J Epidemiol       Date:  2019-10-17       Impact factor: 8.082

4.  Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months.

Authors:  G De Serres; N Boulianne; F Meyer; B J Ward
Journal:  Epidemiol Infect       Date:  1995-10       Impact factor: 2.451

5.  The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy.

Authors:  Peter Aaby; Cesário L Martins; May-Lill Garly; Amabelia Rodrigues; Christine S Benn; Hilton Whittle
Journal:  BMJ Open       Date:  2012-07-19       Impact factor: 2.692

6.  Measles 2018: a tale of two anniversaries.

Authors:  Philippe J Sansonetti
Journal:  EMBO Mol Med       Date:  2018-05       Impact factor: 12.137

7.  Invalid measles vaccine dose administration and vaccine effectiveness in Ethiopia.

Authors:  Teklay Desta; Ephrem Lemango; Daddi Wayessa; Liya Wondowossen; Mirkuzie Kerie; Balcha Masresha
Journal:  Pan Afr Med J       Date:  2021-12-16

8.  The optimal vaccination strategy to control COVID-19: a modeling study in Wuhan City, China.

Authors:  Ze-Yu Zhao; Yan Niu; Li Luo; Qing-Qing Hu; Tian-Long Yang; Mei-Jie Chu; Qiu-Ping Chen; Zhao Lei; Jia Rui; Cheng-Long Song; Sheng-Nan Lin; Yao Wang; Jing-Wen Xu; Yuan-Zhao Zhu; Xing-Chun Liu; Meng Yang; Jie-Feng Huang; Wei-Kang Liu; Bin Deng; Chan Liu; Zhuo-Yang Li; Pei-Hua Li; Yan-Hua Su; Ben-Hua Zhao; Wen-Long Huang; Roger Frutos; Tian-Mu Chen
Journal:  Infect Dis Poverty       Date:  2021-12-28       Impact factor: 4.520

9.  Epidemiology of measles in the metropolitan setting, Addis Ababa, Ethiopia, 2005-2014: a retrospective descriptive surveillance data analysis.

Authors:  Munira Nasser Hassen; Abyot Bekele Woyessa; Mekonen Getahun; Berhane Beyene; Lucy Buluanger; Ayesheshem Ademe; Alemayehu Bekele; Adamu Addissie; Amha Kebede; Daddi Jima
Journal:  BMC Infect Dis       Date:  2018-08-14       Impact factor: 3.090

10.  Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis.

Authors:  Laura M Nic Lochlainn; Brechje de Gier; Nicoline van der Maas; Rob van Binnendijk; Peter M Strebel; Tracey Goodman; Hester E de Melker; William J Moss; Susan J M Hahné
Journal:  Lancet Infect Dis       Date:  2019-09-20       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.